EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of dihydroartemisinin-piperaquine after 10 years as treatment for vivax malaria in Indonesia

Fanny Arcelia, Ayodhia Pitaloka Pasaribu, Gema Nazri Yanni

The Journal of Infection in Developing Countries · 2023

DOI: 10.3855/jidc.16391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2023. Verfasst von Fanny Arcelia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child Health, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia. Hauptthemen laut MEDLINE: Malaria, Vivax, Antimalarials, Malaria, Malaria, Falciparum. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dihydroartemisin-piperaquine (DHP) is a type of artemisinin-based combination therapy (ACT) that is extensively used in Indonesia as first-line malaria treatment over the past 10 years. Therefore, DHP has been known to have high efficacy, but re-evaluation of the efficacy was needed since the treatment was being used for a long time. Methodology: A cohort prospective study on pediatric and adult patients diagnosed with vivax malaria in Kualuh Leidong health centre was conducted from November 2019 – April 2020 to evaluate the efficacy of DHP for the treatment of malaria vivax. The efficacy of DHP was monitored by evaluating the clinical symptoms and serial peripheral blood smear at day 1,2,3,7,14,21 and 28.

Results

A total of 60 children and adults diagnosed with malaria vivax were enrolled for this study. Major symptoms such as fever, sweating and dizziness were found in all of subjects. The mean number of parasites on day 0 of observation in the child and adult groups was 313.33/µL and 328/µL respectively (p = 0.839). Meanwhile, the mean number of gametocytes on day 0 was 74109.33/µL in the child group and 61661.33/µL in the adult group. There was a reduction in the number of gametocytes on the 1st day of observation in the child and adult groups to 669.33/µL and 489.33/µL respectively (p = 0.512). No recrudescence occurred in either group within 28 days of observation.

Conclusions

DHP is still efficacious and safe as a first-line treatment for vivax malaria in Indonesia, with 100% cure rate at 28 days of observation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, VivaxAntimalarialsMalariaMalaria, FalciparumAdultHumansChildProspective StudiesIndonesiaArtemisininsPiperazinesQuinolines

Stichwörter der Autor:innen

Plasmodium vivaxdihydroartemisinin-piperaquinemalaria

Substanzen

AntimalarialsartenimolArtemisininspiperaquinePiperazinesQuinolines

Autor:innen und Institutionen

  • Department of Child Health, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.

Zitieren

APA

Arcelia, F., Pasaribu, A. P., & Yanni, G. N. (2023). Effectiveness of dihydroartemisinin-piperaquine after 10 years as treatment for vivax malaria in Indonesia. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.16391

Vancouver

Arcelia F, Pasaribu AP, Yanni GN. Effectiveness of dihydroartemisinin-piperaquine after 10 years as treatment for vivax malaria in Indonesia. The Journal of Infection in Developing Countries. 2023. doi:10.3855/jidc.16391

BibTeX
@article{Arcelia2023,
  author = {Arcelia, Fanny and Pasaribu, Ayodhia Pitaloka and Yanni, Gema Nazri},
  title = {Effectiveness of dihydroartemisinin-piperaquine after 10 years as treatment for vivax malaria in Indonesia},
  journal = {The Journal of Infection in Developing Countries},
  year = {2023},
  doi = {10.3855/jidc.16391}
}
Kostenlos starten →